Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
A legfontosabb adatok
- Ki végzi
- Woolfson Eye Institute
- Hol
- Asheville, Atlanta, Canton, Chattanooga, Cumming, Douglasville, Johnson City, Knoxville, Lawrenceville, Marietta és Snellville (Egyesült Államok)Mind a 11 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 485 fő, tervezett
- Kezdés
- 2025. aug. 1.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Epi-ON corneal cross-linking
- A regiszteradat frissítve
- 2026. február 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 8 or older with a cornea that becomes thin and misshapen, such as keratoconus. They will get corneal crosslinking with UVA light for either 18 or 24 minutes.
- Életkor
- 8 years or older. Children under 14 sign an assent, and a parent or guardian signs consent.
- Nem
- All sexes can join.
- A betegség stádiuma
- Keratoconus, ectasia after LASIK or PRK, pellucid marginal degeneration, progressive ectasia after earlier CXL, or forme fruste keratoconus. The diagnosis must be based on corneal scans and slit lamp exam.
- Korábbi kezelés
- People who had a corneal transplant in the study eye cannot join. People with ectasia that progressed after earlier CXL can join.
- Biomarker vagy leletérték
- Thinnest corneal thickness must not be below 300 (measured by Pentacam and Ultrasound).
A részvétel fő kizáró okai
- Normal corneal shape on topography
- Past or active corneal disease such as herpes, or major scarring in the central cornea
- Nystagmus or other condition that stops a steady gaze
- Pregnant, nursing or planning a pregnancy
- Unable to stop wearing contact lenses before exams (3 days for soft or scleral, 2 weeks for rigid gas-permeable)
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects in whom both the subject and study eye meet all of the following criteria are candidates for the study:
- Be at least 8 years of age or older, male or female, of any race
- Have a diagnosis of keratoconus, ectasia after LASIK, ectasia after PRK, pellucid marginal degeneration, progressive ectasia after previous CXL treatment or forme fruste keratoconus based on topography, tomography, and slit lamp examination
- Provide written informed consent and a signed HIPAA form. Pediatric subjects less than 14 years of age must sign an assent, and a parent or legal guardian must sign an informed consent
- Be willing and able to follow all instructions and comply with the schedule for follow-up visits
- If female and capable of becoming pregnant, must not be lactating or pregnant and must agree to use a medically acceptable form of birth control for at least one week prior to the treatment visit and to continue one month following treatment
Ki nem vehet részt
- A history of previous corneal transplant in the study eye
- Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye to future complications or prevent the possibility of improved vision, for example:; History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.); Clinically significant corneal scarring in the central cornea that, in the investigator's opinion, will not allow the subject to achieve functional vision, even with contact lens correction, after the crosslinking procedure
- If female, pregnant, nursing or planning a pregnancy, or having a positive urine pregnancy test prior to the randomization of, or treatment of either eye during the course of the study
- Inability to remove soft or scleral contact lenses at least 3 days before initial and follow-up examinations
- Inability to remove rigid gas-permeable contact lenses at least 2 weeks before initial and follow-up examinations
- A known contraindication, sensitivity, or allergy to the test article or its components or to study medications
- Nystagmus or any other condition that would prevent a steady gaze during the crosslinking treatment or other diagnostic tests
- Presence or history or any other condition or finding that, in the investigator's opinion, makes the subject unsuitable as a candidate for crosslinking or study participation or may confound the outcome of the study
- Subjects in whom the subject or study eye meets one or more of the following criteria will be excluded from the randomized cohort of the study:
- Normal corneal topography
- Minimum corneal thickness < 300 (measured by Pentacam and Ultrasound) at the screening exam
- Inability to return for required postoperative examinations
Helyszínek itt: Egyesült Államok
- Woolfson Eye InstituteAsheville, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteAtlanta, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteCanton, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteChattanooga, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteCumming, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteDouglasville, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteJohnson City, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteKnoxville, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteLawrenceville, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteMarietta, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
- Woolfson Eye InstituteSnellville, Egyesült ÁllamokContact: LuAnn BryantRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to study the effects of an experimental (not Food and Drug Administration (FDA)-approved) treatment called corneal crosslinking (CXL) for conditions in which the cornea becomes progressively thin, steep, and misshapen, causing vision to be blurred.
A teljes eredeti leírásKevesebb
CXL is performed by putting riboflavin (vitamin B2) drops onto the eye and then exposing it to ultraviolet (UVA) light at about the same intensity as you get outdoors on a bright, sunny day. It is designed to stop the progression of disease by strengthening the cornea. Study participants will be at least 8 years of age or older and have a diagnosis of keratoconus, ectasia after LASIK, ectasia after PRK, pellucid marginal degeneration, progressive ectasia after previous CXL treatment or forme fruste keratoconus.
The main question it aims to answer is:
* Does CXL help prevent or slow the progression of someone's corneal condition and vision loss?
Participants will:
* Attend up to a total of 7 in office visits over the course of 6 months, where several eye and vision tests will be given.
Receive CXL (applying riboflavin (Vitamin B2 eye drops) to the eye, then exposing the eye to ultraviolet (UV-A) light).
* There will be two groups of participants. One group will receive the UVA treatment for 18 minutes and the other group will receive the UVA treatment for 24 minutes.
A vizsgálat 2 csoportja
- UVA 18 minuteA vizsgált kezelés
Subjects who meet the inclusion criteria and provide informed consent will be randomized to receive UVA irradiation with 15-second off-on cycling for either 18 minutes or 24 minutes
Kezelés: Epi-ON corneal cross-linking
- UVA 24 minuteA vizsgált kezelés
Subjects who meet the inclusion criteria and provide informed consent will be randomized to receive UVA irradiation with 15-second off-on cycling for either 18 minutes or 24 minutes
Kezelés: Epi-ON corneal cross-linking
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure Versus a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. február 2.